CASC3 (Gene)

Organism:

Homo sapiens

Synonyms:BTZ, CASC3 exon junction complex subunit, CASC3, ENTREZ:22794, HGNC:17040, MIM:606504, MLN51, NM_007359, NP_031385, XM_005257163, XP_005257220, XR_001752451, XR_002957984, XR_002957985, XR_934422

Omim:OMIM:606504

Id:a47d2389-d264-560b-b2bc-85660dfe9f03

Hgnc:HGNC:17040

Entrez:22794

Ensembl:ENSG00000108349

Description:CASC3 exon junction complex subunit

The product of this gene is a core component of the exon junction complex (EJC), a protein complex that is deposited on spliced mRNAs at exon-exon junctions and functions in nonsense-mediated mRNA decay (NMD). The encoded protein binds RNA and interacts with two other EJC core components. It is predominantly located in the cytoplasm, but shuttles into the nucleus where it localizes to nuclear speckles. [provided by RefSeq, Jul 2008]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CASC3's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CASC3.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CASC3.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CASC3.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CASC3.

Results found

Linked to

	Label	Description
	GSE120612 etoposide leukocyte 6 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE242555 1 V 0 NICOTINAMIDE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE228727 2 V 1 DAPAGLIFLOZIN MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE207871 NPC knockdown S18 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE226285 3 V 0 GLUTATHIONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 8 V 7 SAHA HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 6 V 5 CRIZOTINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE226249 5 V 4 PIRFENIDONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 12 V 6 PALMITIC ACID HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS

GSE120612 etoposide leukocyte 6 v 1 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE242555 1 V 0 NICOTINAMIDE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE228727 2 V 1 DAPAGLIFLOZIN MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE207871 NPC knockdown S18 1 v 0 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE226285 3 V 0 GLUTATHIONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 8 V 7 SAHA HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE239844 6 V 5 CRIZOTINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE226249 5 V 4 PIRFENIDONE HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE158834 12 V 6 PALMITIC ACID HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.